<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Sarepta-Therapeutics-Inc-US8036071004">Sarepta Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260630221318/en/Sarepta-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4/">Sarepta Therapeutics gewährt Anstellungsboni nach Nasdaq-Listing-Regel 5635(c)(4)</a>
    </div>

      <div class="me-0 me-md-5">
        CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), führend in präziser Gentherapie für seltene Krankheiten, gewährte am 30. Juni 2026 Aktienzuwendungen, die zuvor vom Vergütungsausschuss ihres Vorstands im Rahmen des Sarepta 2024 Employment Commencement Incentive Plan genehmigt worden waren, als wesentliche Anreize zur Einstellung von 30 Personen, die Sarepta im zweite...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Sarepta-Therapeutics-Inc-US8036071004">Sarepta Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260630779541/en/Sarepta-Announces-FDA-Acceptance-of-sNDAs-for-AMONDYS-45%C2%AE-and-VYONDYS-53%C2%AE/">Sarepta meldet FDA-Akzeptanz von sNDAs für AMONDYS 45® und VYONDYS 53®</a>
    </div>

      <div class="me-0 me-md-5">
        CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), der führende Anbieter präziser Gentherapien für seltene Krankheiten, gab heute bekannt, dass die U.S. Food and Drug Administration (FDA) die Ergänzenden New Drug Applications (sNDAs) für AMONDYS 45® (casimersen) und VYONDYS 53® (golodirsen) zur Behandlung der Duchenne-Muskeldystrophie (DMD) zur Einreichung akzeptiert h...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Sarepta-Therapeutics-Inc-US8036071004">Sarepta Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260601633179/en/Sarepta-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences/">Sarepta Therapeutics to Participate in Upcoming Investor Conferences</a>
    </div>

      <div class="me-0 me-md-5">
        CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Fireside chat: Monday, June 8, at 10:40 a.m. ET at the Loews Miami Beach Hotel in Miami Beach, Fla. Op...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Sarepta-Therapeutics-Inc-US8036071004">Sarepta Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260513196589/en/Sarepta-Therapeutics-to-Present-at-the-RBC-Capital-Markets-Global-Healthcare-Conference/">Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference</a>
    </div>

      <div class="me-0 me-md-5">
        CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference at the InterContinental New York Barclay on Wednesday, May 20, at 8:30 a.m. ET. The presentations will be webcast live under the ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Sarepta-Therapeutics-Inc-US8036071004">Sarepta Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260422642254/en/Sarepta-Therapeutics-to-Announce-First-Quarter-2026-Financial-Results/">Sarepta Therapeutics to Announce First Quarter 2026 Financial Results</a>
    </div>

      <div class="me-0 me-md-5">
        CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results. The event will be webcast live under the invest...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Sarepta-Therapeutics-Inc-US8036071004">Sarepta Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">24/7 Wall Street</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://247wallst.com/investing/2026/04/01/5-biotechs-that-big-pharma-could-snap-up-as-oncology-ma-heats-up/?utm_source=snapi">5 Biotechs That Big Pharma Could Snap Up as Oncology M&amp;A Heats Up</a>
    </div>

      <div class="me-0 me-md-5">
        Oncology M&amp;A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Sarepta-Therapeutics-Inc-US8036071004">Sarepta Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260331816781/en/Sarepta-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4/">Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</a>
    </div>

      <div class="me-0 me-md-5">
        CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta&#39;s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Sarepta-Therapeutics-Inc-US8036071004">Sarepta Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">24/7 Wall Street</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://247wallst.com/investing/2026/03/29/mrna-srpt-and-krys-phase-3-data-will-shape-xbis-2026-performance/?utm_source=snapi">MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI&#39;s 2026 Performance</a>
    </div>

      <div class="me-0 me-md-5">
        SPDR S&amp;P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Sarepta-Therapeutics-Inc-US8036071004/load_more?page=3">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>